SynthesisJournal of global health2025
Human West Nile virus infection: a meta-analysis of recent global data (2019-24).
Synthesis in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Forgotten in the tropics: research on Culex mosquitoes is overshadowed in malaria and dengue-endemic regions.Parasites & vectors · 2026Pooled it
- Prevalence and characterization of West Nile virus infections among people living with HIV in Northern Italy: a sero-repository analysis.Infection · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: West Nile virus (WNV), an arbovirus of significant public health concern, is widely distributed across various regions, especially in Africa, Asia, Europe, and North America. However, the current global prevalence is unknown. We aim to provide an update on the recent prevalence of human WNV infection. Methods: We performed a systematic review and meta-analysis that adhered to standard reporting guidelines to offer a comprehensive overview of the virus's prevalence worldwide. We systematically searched four electronic databases, extracted relevant data, and computed pooled prevalence estimates using the DerSimonian-Laird random-effects model. We conducted subgroup and meta-regression analyses by region and study population and assessed study quality with the Joanna Briggs Institute critical appraisal tool for prevalence studies. Results: The global pooled seroprevalence of human WNV, based on studies using confirmatory neutralisation assays, was estimated at 3.6% (95% confidence interval (CI) = 2.0, 6.5), with a notably higher rate in North America (18.8%; 95% CI = 14.4, 24.1), followed by Africa (4.8%; 95% CI = 1.7, 13.2). South America had the least seroprevalence (1.7%; 95% CI = 0.9, 3.4). Based on the specific participant population, seroprevalence rates were found to be 4.7% (95% CI = 1.7, 12.6) among blood donors, 3.2% (95% CI = 1.0, 10.4) among clinical patients, and 2.3% (95% CI = 1.2, 4.4) among high-risk individuals. The global pooled molecular prevalence was estimated to be 0.1% (95% CI = 0.00, 0.02). Conclusions: While the global WNV prevalence rates are relatively low, targeted interventions are needed. These findings underscore the urgency of enhancing blood donor screening in high-seroprevalence regions, integrating advanced diagnostics (e.g. nucleic acid tests) into surveillance systems, and harmonising global reporting protocols to mitigate cross-border transmission risks. Registration: PROSPERO: CRD42024555398.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.